Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 1.00 |
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | POLB | P06746 | 2/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | PKM | P14618 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.53 |
| ▸ | RELA | Q04206 | 1/20 | 0.53 |
| ▸ | CNR1 | P21554 | 2/20 | 0.52 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9282775 | 1.00 | HTT (1.00) | HTTGAAPOLBLMNACYP2C9 | |
| SCHEMBL2399935 | 0.98 | HTT (0.96) | HTTGAAPOLBLMNACYP2C9 | |
| SCHEMBL4612423 | 0.87 | HTT (0.77) | HTTPOLBLMNACYP2C9SMN1; SMN2 | |
| SCHEMBL5406540 | 0.85 | HTT (0.73) | HTTGAAPOLBLMNASMN1; SMN2 | |
| SCHEMBL1576773 | 0.81 | CYP2D6 (0.71) | HTTGAALMNACYP2C9SMN1; SMN2 | |
| SCHEMBL717372 | 0.81 | HTT (0.69) | HTTGAAPOLBCYP2C9SMN1; SMN2 | |
| SCHEMBL2999120 | 0.81 | HTT (0.69) | HTTGAAPOLBLMNACYP2C9 | |
| SCHEMBL12629113 | 0.81 | CYP2D6 (0.71) | HTTGAALMNACYP2C9HPGD | |
| SCHEMBL7716857 | 0.81 | HTT (0.69) | HTTGAALMNACYP2C9SMN1; SMN2 | |
| SCHEMBL3955220 | 0.81 | SMN1; SMN2 (0.71) | HTTGAAPOLBLMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1022830-C | Preparation of benzamides | FORDONAL SA (ES) | 1993-11-24 | — | — | CN | claimed |
| CN-86105972-A | Novel benzamides | — | 1987-04-01 | — | — | CN | claimed |
| CN-114302880-A | KIF18A inhibitors | 美国安进公司 | 2022-04-08 | — | — | CN | disclosed |
| EP-3373920-A1 | METHODS AND COMPOSITIONS FOR TREATING ALCOHOL USE DISORDERS | Sanna, Pietro Paolo (US) | 2018-09-19 | — | — | EP | disclosed |
| US-10039772-B2 | Methods and compositions for treating alcohol use disorders | SANNA PIETRO PAOLO (US) | 2018-08-07 | — | — | US | disclosed |
| CN-107820494-A | Nuclear receptor modulators | 艾伯维公司 | 2018-03-20 | — | — | CN | disclosed |
| US-20170232007-A1 | METHODS AND COMPOSITIONS FOR TREATING ALCOHOL USE DISORDERS | SANNA PIETRO PAOLO (US) | 2017-08-17 | — | — | US | disclosed |
| WO-2017083795-A1 | METHODS AND COMPOSITIONS FOR TREATING ALCOHOL USE DISORDERS | SANNA PIETRO PAOLO (US) | 2017-05-18 | — | — | WO | disclosed |
| EP-2123769-B1 | METHOD FOR PRODUCING OPTICALLY ACTIVE 3-AMINOPIPERIDINE OR SALT THEREOF | KANEKA CORP (JP) | 2016-05-18 | — | — | EP | disclosed |
| CN-102656141-B | Micromolecular compound of simulation hemopoieticgrowth factor and uses thereof | LIGAND PHARMACEUTICALS INC. (US) | 2016-04-06 | — | — | CN | disclosed |
| US-20150166481-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE 3-AMINOPIPERIDINE OR SALT THEREOF | KANEKA CORPORATION (JP) | 2015-06-18 | — | — | US | disclosed |
| EP-0251417-A2 | 4-(aroylamino) piperidinebutanamide derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 1988-01-07 | — | — | EP | disclosed |
| US-4717563-A | 2-alkoxy-N-(1-azabicyclo(2.2.2)oct-3-yl) benzamides and thiobenzamides in a method for alleviating emesis caused by non-platinum anticancer drugs | A. H. ROBINS COMPANY, INC. (US) | 1988-01-05 | — | — | US | disclosed |
| EP-0240180-A1 | 2-alkoxy-N-(1-azabicyclo[2.2.2]-oct-3-yl) benzamides and thiobenzamides in the alleviation of emesis caused by non-platinum anticancer drugs | SYNTHELABO (FR) | 1987-10-07 | — | — | EP | disclosed |
| US-4593034-A | 2-alkoxy-N-(1-azabicyclo[2.2.2]oct-3-yl)benzamides and thiobenzamides | A. H. ROBINS COMPANY, INC. (US) | 1986-06-03 | — | — | US | disclosed |
| EP-0076530-B1 | NOVEL N-(3-HYDROXY-4-PIPERIDINYL)BENZAMIDE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 1985-12-11 | — | — | EP | disclosed |
| EP-0158532-A2 | Use of 4-amino-N-(1-azabicyclo[2.2.2]oct-3-yl)-5-chloro-2-methoxybenzamide for the manufacture of a medicament having anti-emetic activity. | SYNTHELABO (FR) | 1985-10-16 | — | — | EP | disclosed |
| EP-0076530-A2 | Novel N-(3-hydroxy-4-piperidinyl)benzamide derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 1983-04-13 | — | — | EP | disclosed |
| US-4097487-A | CNS DEPRESSANTS, ANTIPSYCHOTICS | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JA) | 1978-06-27 | — | — | US | disclosed |
| US-4028352-A | TREATMENT OF CARDIOVASCULAR DISEASES | JOHN WYETH & BROTHER LIMITED (EN) | 1977-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10039772-B2 | Methods and compositions for treating alcohol use disorders | HSD3B1, HSD11B1, HSD3B2 | HTT 3015/4885GAA 2212/4885POLB 3388/4885 |
| US-20170232007-A1 | METHODS AND COMPOSITIONS FOR TREATING ALCOHOL USE DISORDERS | HSD3B1, HSD11B1, HSD3B2 | HTT 3015/4885GAA 2212/4885POLB 3388/4885 |
| US-20150166481-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE 3-AMINOPIPERIDINE OR SALT THEREOF | NPEPPS, APEH, DNPEP | HTT 376/4885GAA 131/4885POLB 1716/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.